Macrophage Depletion Blocks Congenital SARM1-dependent Neuropathy

Caitlin B. Dingwall,Amy Strickland,Sabrina W. Yum,Aldrin K. Y. Yim,Jian Zhu,Peter L. Wang,Yurie Yamada,Robert E. Schmidt,Yo Sasaki,A. Joseph Bloom,Aaron DiAntonio,Jeffrey Milbrandt

DOI: https://doi.org/10.1172/jci159800

2022-01-01

Abstract:Axon loss contributes to many common neurodegenerative disorders. In healthy axons, the axon survival factor NMNAT2 inhibits SARM1, the central executioner of programmed axon degeneration. We identified 2 rare NMNAT2 missense variants in 2 brothers afflicted with a progressive neuropathy syndrome. The polymorphisms resulted in amino acid substitutions V98M and R232Q, which reduced NMNAT2 NAD+-synthetase activity. We generated a mouse model to mirror the human syndrome and found that Nmnat2V98M/R232Q compound-heterozygous CRISPR mice survived to adulthood but developed progressive motor dysfunction, peripheral axon loss, and macrophage infiltration. These disease phenotypes were all SARM1-dependent. Remarkably, macrophage depletion therapy blocked and reversed neuropathic phenotypes in Nmnat2V98M/R232Q mice, identifying a SARM1-dependent neuroimmune mechanism as a key driver of disease pathogenesis. These findings demonstrate that SARM1 induced inflammatory neuropathy and highlight the potential of immune therapy as a treatment for this rare syndrome and other neurodegenerative conditions associated with NMNAT2 loss and SARM1 activation.